Sumitomo

Photo

Sumitovant Closes Myovant Purchase

US biopharma Sumitovant – a wholly owned subsidiary of Japan’s Sumitomo Pharma – has closed its purchase of the remaining equity in Myovant Sciences, taking full control of the Swiss clinical-stage biopharma for about $1.7 billion. Myovant will now be delisted from the New York Stock Exchange.

Photo

Yara and Sumitomo Collaborate on Clean Ammonia

Fertilizer giant Yara has entered into a Memorandum of Understanding (MoU) with Sumitomo Chemical under which the Norwegian group will examine the supply of clean ammonia to the Japanese firm’s production plants. Sumitomo would use the clean ammonia for producing petrochemicals and plastics and/or distributing energy out of its plants in Japan.

Photo

Rentschler Biopharma Extends Japanese Pact

German biopharmaceuticals contract development and manufacturing organization Rentschler Biopharma is extending and deepening its existing collaboration in Japan with Summit Pharmaceuticals International (SPI), a wholly owned subsidiary of Sumitomo.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.